- Oxaliplatin induces apoptosis in hepatocellular carcinoma cells and inhibits tumor growth
[作者:Wang, Z; Zhou, J; Fan, J; Qiu, SJ; Yu, Y; Huang, XW; Sun, J; Tan, CJ; Dai, Z,期刊:Expert opinion on investigational drugs, 页码:1595-1604 , 文章类型: Article,,卷期:2009年18-11]
- Objective: The platinum-based chemotherapeutic agent oxaliplatin displays a wide range of antitumor activities. To date, no detailed data are available about the effects of oxaliplatin on hepatocellular carcinoma (HCC) c...
- Targeting of HDAC8 and investigational inhibitors in neuroblastoma
[作者:Oehme, I; Deubzer, HE; Lodrini, M; Milde, T; Witt, O,期刊:Expert opinion on investigational drugs, 页码:1605-1617 , 文章类型: Review,,卷期:2009年18-11]
- Histone deacetylase (HDAC) inhibitors are an emerging class of promising novel anticancer drugs. However, little is known which one of the 11 classical HDAC family members is the most relevant drug target for therapy. Th...
- Investigating the role of PDGF as a potential drug therapy in bone formation and fracture healing
[作者:Graham, S; Leonidou, A; Lester, M; Heliotis, M; Mantalaris, A; Tsiridis, E,期刊:Expert opinion on investigational drugs, 页码:1633-1654 , 文章类型: Review,,卷期:2009年18-11]
- Background: Platelet-derived growth factor (PDGF) has been shown in vivo to increase bone formation and supplement fracture healing, and may have a role as a therapeutic agent in the treatment of bone loss and fracture h...
- Will treatment of rheumatoid arthritis with an IL-6R inhibitor help facilitate the 'age of remission'?
[作者:Moots, RJ; Ostor, AJK; Isaacs, JD,期刊:Expert opinion on investigational drugs, 页码:1687-1699 , 文章类型: Review,,卷期:2009年18-11]
- Background: Rheumatoid arthritis (RA) is a chronic, inflammatory, systemic disease, which negatively influences patients' quality of life, work productivity and longevity. Current therapies include traditional and biolog...
- Antivascular agents for non-small-cell lung cancer: current status and future directions
[作者:Amir, E; Mandoky, L; Blackhall, F; Thatcher, N; Klepetko, W; Ankersmit, HJ; Hoda, MAR; Ostoros, G; Dank, M; Dome, B,期刊:Expert opinion on investigational drugs, 页码:1667-1686 , 文章类型: Review,,卷期:2009年18-11]
- Background: Despite improvements in surgery and chemo(radio)therapy which have allowed for modest advances in the treatment of patients with non-small-cell lung cancer (NSCLC) survival remains poor and further improvemen...
- Darinaparsin: a novel organic arsenical with promising anticancer activity
[作者:Mann, KK; Wallner, B; Lossos, IS; Miller, WH,期刊:Expert opinion on investigational drugs, 页码:1727-1734 , 文章类型: Editorial Material,,卷期:2009年18-11]
- Darinaparsin is an organic arsenical composed of dimethylated arsenic linked to glutathione, and is being investigated for antitumor properties in vitro and in vivo. While other arsenicals, including arsenic trioxide, ha...
- Vicriviroc: a CCR5 antagonist for treatment-experienced patients with HIV-1 infection
[作者:Kummerle, T; Lehmann, C; Hartmann, P; Wyen, C; Fatkenheuer, G,期刊:Expert opinion on investigational drugs, 页码:1773-1785 , 文章类型: Editorial Material,,卷期:2009年18-11]
- Background: Despite the availability of 31 antiretroviral agents or fixed-dose combinations in the United States and European Union, there is a continuing need for antiretroviral agents with high genetic barriers to resi...
|